ASTH
Price
$28.82
Change
-$0.97 (-3.26%)
Updated
Sep 19, 12:06 PM (EDT)
Capitalization
1.37B
41 days until earnings call
EXETF
Price
$9.64
Change
-$0.02 (-0.21%)
Updated
Sep 18 closing price
Capitalization
815.01M
54 days until earnings call
Interact to see
Advertisement

ASTH vs EXETF

Header iconASTH vs EXETF Comparison
Open Charts ASTH vs EXETFBanner chart's image
Astrana Health
Price$28.82
Change-$0.97 (-3.26%)
Volume$100
Capitalization1.37B
Extendicare
Price$9.64
Change-$0.02 (-0.21%)
Volume$2.61K
Capitalization815.01M
ASTH vs EXETF Comparison Chart in %
Loading...
ASTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EXETF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ASTH vs. EXETF commentary
Sep 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASTH is a Hold and EXETF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 19, 2025
Stock price -- (ASTH: $29.78 vs. EXETF: $9.64)
Brand notoriety: ASTH and EXETF are both not notable
Both companies represent the Hospital/Nursing Management industry
Current volume relative to the 65-day Moving Average: ASTH: 71% vs. EXETF: 92%
Market capitalization -- ASTH: $1.37B vs. EXETF: $815.01M
ASTH [@Hospital/Nursing Management] is valued at $1.37B. EXETF’s [@Hospital/Nursing Management] market capitalization is $815.01M. The market cap for tickers in the [@Hospital/Nursing Management] industry ranges from $93.85B to $0. The average market capitalization across the [@Hospital/Nursing Management] industry is $4.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASTH’s FA Score shows that 1 FA rating(s) are green whileEXETF’s FA Score has 3 green FA rating(s).

  • ASTH’s FA Score: 1 green, 4 red.
  • EXETF’s FA Score: 3 green, 2 red.
According to our system of comparison, EXETF is a better buy in the long-term than ASTH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ASTH’s TA Score shows that 4 TA indicator(s) are bullish while EXETF’s TA Score has 5 bullish TA indicator(s).

  • ASTH’s TA Score: 4 bullish, 5 bearish.
  • EXETF’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, EXETF is a better buy in the short-term than ASTH.

Price Growth

ASTH (@Hospital/Nursing Management) experienced а -1.97% price change this week, while EXETF (@Hospital/Nursing Management) price change was +3.21% for the same time period.

The average weekly price growth across all stocks in the @Hospital/Nursing Management industry was -0.85%. For the same industry, the average monthly price growth was +119.40%, and the average quarterly price growth was +85.59%.

Reported Earning Dates

ASTH is expected to report earnings on Oct 30, 2025.

EXETF is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Hospital/Nursing Management (-0.85% weekly)

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ASTH($1.38B) has a higher market cap than EXETF($815M). ASTH has higher P/E ratio than EXETF: ASTH (57.27) vs EXETF (13.73). EXETF YTD gains are higher at: 32.600 vs. ASTH (-5.550). EXETF has higher annual earnings (EBITDA): 164M vs. ASTH (112M). ASTH has more cash in the bank: 342M vs. EXETF (72.6M). EXETF has less debt than ASTH: EXETF (284M) vs ASTH (448M). ASTH has higher revenues than EXETF: ASTH (2.42B) vs EXETF (1.51B).
ASTHEXETFASTH / EXETF
Capitalization1.38B815M169%
EBITDA112M164M68%
Gain YTD-5.55032.600-17%
P/E Ratio57.2713.73417%
Revenue2.42B1.51B160%
Total Cash342M72.6M471%
Total Debt448M284M158%
FUNDAMENTALS RATINGS
ASTH vs EXETF: Fundamental Ratings
ASTH
EXETF
OUTLOOK RATING
1..100
6819
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
8
Undervalued
PROFIT vs RISK RATING
1..100
8825
SMR RATING
1..100
8817
PRICE GROWTH RATING
1..100
6153
P/E GROWTH RATING
1..100
1650
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXETF's Valuation (8) in the null industry is significantly better than the same rating for ASTH (76). This means that EXETF’s stock grew significantly faster than ASTH’s over the last 12 months.

EXETF's Profit vs Risk Rating (25) in the null industry is somewhat better than the same rating for ASTH (88). This means that EXETF’s stock grew somewhat faster than ASTH’s over the last 12 months.

EXETF's SMR Rating (17) in the null industry is significantly better than the same rating for ASTH (88). This means that EXETF’s stock grew significantly faster than ASTH’s over the last 12 months.

EXETF's Price Growth Rating (53) in the null industry is in the same range as ASTH (61). This means that EXETF’s stock grew similarly to ASTH’s over the last 12 months.

ASTH's P/E Growth Rating (16) in the null industry is somewhat better than the same rating for EXETF (50). This means that ASTH’s stock grew somewhat faster than EXETF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ASTHEXETF
RSI
ODDS (%)
Bearish Trend 1 day ago
76%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
52%
Momentum
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 1 day ago
56%
MACD
ODDS (%)
Bearish Trend 1 day ago
73%
Bullish Trend 1 day ago
63%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
57%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
54%
Advances
ODDS (%)
Bullish Trend 22 days ago
79%
Bullish Trend 5 days ago
59%
Declines
ODDS (%)
Bearish Trend 5 days ago
73%
Bearish Trend 17 days ago
53%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
62%
Aroon
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
49%
View a ticker or compare two or three
Interact to see
Advertisement
ASTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EXETF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCCVX38.45N/A
N/A
Fidelity Advisor Convertible Secs C
MFRJX63.71N/A
N/A
MFS Research R4
RYAWX115.15N/A
N/A
Rydex S&P 500 Pure Growth H
MRLVX28.84N/A
N/A
BlackRock Advantage Large Cap Val R
TCGCX22.41N/A
N/A
Thornburg Small/Mid Cap Growth C

ASTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, ASTH has been loosely correlated with ACHC. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ASTH jumps, then ACHC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASTH
1D Price
Change %
ASTH100%
+2.41%
ACHC - ASTH
47%
Loosely correlated
+0.68%
DCGO - ASTH
40%
Loosely correlated
+4.39%
AMN - ASTH
36%
Loosely correlated
+1.32%
LFST - ASTH
35%
Loosely correlated
+4.27%
AIRS - ASTH
33%
Loosely correlated
-0.65%
More

EXETF and

Correlation & Price change

A.I.dvisor tells us that EXETF and FSNUF have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EXETF and FSNUF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXETF
1D Price
Change %
EXETF100%
-0.18%
FSNUF - EXETF
28%
Poorly correlated
N/A
AIRS - EXETF
27%
Poorly correlated
-0.65%
INNV - EXETF
23%
Poorly correlated
+1.81%
ASTH - EXETF
22%
Poorly correlated
+2.41%
THC - EXETF
22%
Poorly correlated
+3.72%
More